
    
      Title of study extension: An open-label, multicenter extension to evaluate the efficacy and
      safety of a 4 week therapy with amlodipine 5 mg and aliskiren 300 mg plus HCTZ 25 mg in
      hypertensive patients not adequately responding to a 4 week therapy each with the
      combinations of candesartan 32 mg plus hydrochlorothiazide 25 mg followed by aliskiren 300mg
      plus hydrochlorothiazide 25 mg
    
  